功能变异的CREB3增益可以保护ALS
Salim Megat1, Christine Marques2, Marina Hernán-Godoy2
1Université de Strasbourg, Inserm, Strasbourg Translational Neuroscience and Psychiatry, Inserm UMR-S 1329, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, France. salim.megat@inserm.fr.
Nature communications
|March 27, 2025
概括
肌缩侧面硬化症 (ALS) 研究揭示了转录因子CREB3作为弹性标志物. 一种罕见的CREB3变体 (CREB3R119G) 可能降低ALS风险并减缓疾病的进展.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种致命的神经退行性疾病,其特征是运动神经元损失.
- 了解ALS病原体背后的分子机制对于开发有效疗法至关重要.
研究的目的:
- 确定与ALS中皮质脊髓神经元 (CSN) 弹性相关的分子标记物.
- 研究转录因子CREB3及其变体在ALS中的作用.
- 探索CREB3在ALS中的治疗潜力.
主要方法:
- 使用从人类死后组织中获得的snRNA-seq数据进行CSN的比较跨物种转录组学.
- 从Sod1G86R小鼠模型的纯化CSN上的纵向RNA-seq.
- 对ALS患者的遗传和流行病学分析.
- 对CREB3R119G变种的功能获取研究.
主要成果:
- 在ALS中,CSN表现出脑内质网膜 (ER) 应激和改变的mRNA转化.
- 转录因子CREB3及其网络被确定为ALS中各种细胞类型的弹性标记物.
- 一种罕见的变异,CREB3R119G (rs11538707),在ALS中起到积极的疾病修饰作用.
- 获得CREB3R119G的功能降低了ALS的风险,并减缓了患者的运动进展.
结论:
- CREB3是神经元抵抗ALS的一个关键分子参与者.
- 这种CREB3R119G变种显示出潜在的保护因子,可以防止ALS的发展和进展.
- 准CREB3通路可能为ALS提供一种新的治疗策略.
相关概念视频
Cystic Fibrosis: Pathogenesis
170
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
170
CRISPR and crRNAs
16.4K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
16.4K
Amyloid Fibrils
9.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.1K
Regulated Protein Degradation
2.5K
2.5K
Allosteric Proteins-ATCase
5.6K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.6K


